A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Lori Alexander

doi:10.1177/155989770700700305

Article Figures & Data

Tables

Download powerpoint

Tools

Download PDF

View Full Page PDF

Citation Tools

Cited By...

Keywords

Oncology Clinical Trials

Gastrointestinal Cancers

A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Citation Manager Formats

Thank you for your interest in spreading the word on MD Conference Express.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Message Subject (Your Name) has sent you a message from MD Conference Express

Message Body (Your Name) thought you would like to see the MD Conference Express web site.

Your Personal Message

Article Figures & Data

Tables

Tools

Table of contents

Cited By...

Keywords